| Document |
Document Title |
|
WO/2023/172185A1 |
The present disclosure relates to a compound according to Formula (I) and to a method for producing the compound as well as to the use of the compound as an intermediate in the production of coated nanostructures. The present disclosure ...
|
|
WO/2023/170164A1 |
The present disclosure regards a method for providing labeled single isomeric chemical entity targeting vectors suitable for providing targeting vectors. The method applies specific combinations between a diene and a dienophile with comp...
|
|
WO/2023/170174A1 |
The present disclosure regards a method for providing labeled single isomeric chemical entity targeting vectors suitable for providing targeting vectors. The method applies specific combinations between a diene and a dienophile with comp...
|
|
WO/2023/173074A2 |
Provided herein are compounds and compositions for the treatment of diseases or conditions such as cancer. Also provided herein methods of treating diseases and conditions and methods of making compounds and compositions.
|
|
WO/2023/172187A1 |
The present disclosure relates to a plurality of globular nanostructures. Each nanostructure comprises a central part comprising a polymer framework of monomer residues according to {(OR1)(OR2)PO}2-(C){(CH2)mSi(OR3)3}{(CH2)mSi(OR3)3}, wh...
|
|
WO/2023/173097A2 |
Embodiments of the present disclosure provide compositions and methods for performing positron emission tomography (PET) and, more particularly, to compositions and methods for the development and use of 18F-based PET tracers for use in ...
|
|
WO/2023/171617A1 |
[Problem] The present invention addresses the problem of providing a novel method for, under simpler and stabler conditions, labeling a radionuclide such as 211At at a high radiochemical yield. [Solution] Provided is a method for produci...
|
|
WO/2023/166205A1 |
A radiopharmaceutical composition is here described comprising as the active ingredient copper- 64 in ionic form (64Cu++), in combination with suitable excipients, and/or diluents, having radioconcentration comprised between 50 and 3,500...
|
|
WO/2023/164775A1 |
A compound comprising a prostate specific membrane antigen (PSMA)-targeting moiety of the following formula (I) or of a salt or a solvate thereof. R1 is –R1aR1b– wherein R1a is absent, –CH2–, –O–, or –S–, and R1b is –CH...
|
|
WO/2023/164769A1 |
A radiopharmaceutical 177Lu-DOTATATE compound, a composition comprising one or more ascorbate compounds with the substantial or complete absence of a gentisate compound, a single or multiple dosage kit, and a sealed container are provide...
|
|
WO/2023/166305A1 |
The present invention relates to methods of imaging sites of endometriosis using the radiopharmaceutical agent 99m-maraciclatide. The technetium-99m radiopharmaceutical is suitably prepared from a non-radioactive kit containing the RGD p...
|
|
WO/2023/164777A1 |
Compounds comprising a monocyclic peptide that specifically binds to guanylate cyclase 2C (GUCY2C) and comprises at least two cysteine residues with two sulfide units connected via a 3,5-dimethylenepyrazole moiety. Also disclosed are pha...
|
|
WO/2023/165987A1 |
A precursor marker for radiotracers comprises a marker group MG for covalent or coordinative marking with a radioisotope, three or more targeting vectors TV1, TV2, TV3 for targeting cellular receptors, and three or more linkers L1, L2, L...
|
|
WO/2023/163033A1 |
Provided is a compound that has high binding selectivity to α-synuclein aggregates. The present invention relates to a compound represented by formula (I), (II) or (III), a pharmaceutically acceptable salt thereof, or a solvate of the...
|
|
WO/2023/162946A1 |
The purpose of the present invention is to provide a medical agent which specifically binds to FAPα, is effective in the treatment and diagnosis of tumors or cancers expressing FAPα, for example, in the treatment and diagnosis of solid...
|
|
WO/2023/161840A1 |
A device for treating a tumor, including a needle for insertion into the tumor, a solution generator configured to generate a liquid solution including free radionuclides at a concentration of at least 1*106 atoms per microliter and a pu...
|
|
WO/2022/085570A9 |
The present invention pertains to a method that is for producing a radioactive zirconium labelled complex and that can achieve a high labelling rate in a reaction between a ligand compound and radioactive zirconium ions. The production m...
|
|
WO/2023/163553A1 |
The present invention relates to a compound bearing a photosensitizer and an imidazopyridine derivative, a liposome including the compound, and a photodynamic therapeutic composition containing the compound or liposome. According to exem...
|
|
WO/2023/156775A1 |
The present invention relates to a novel anti-cancer radiopharmaceutical treatment that is particularly suitable for targeting PARP enzyme expressing cancers. The novel treatment involves PARP-targeted Auger-emitting radiopharmaceutical ...
|
|
WO/2023/155454A1 |
The present invention relates to a carbonic anhydrase IX-targeting radioactive diagnostic and therapeutic medicament and a method for preparing same, and in particular, relates to a compound represented by formula (I), or a pharmaceutica...
|
|
WO/2023/157822A1 |
The present invention addresses the problem of providing a novel radio-labeled anti-VEGF antibody that is applicable to nuclear medicine diagnosis or radiotherapy. The complex according to the present invention is a complex of a chelatin...
|
|
WO/2023/152671A1 |
The disclosure concerns a pharmaceutical composition comprising a 225Ac radiolabeled complex formed by a 225Ac radionuclide, and a target binding moiety linked to a chelating agent; and a bismuth sequestering agent, typically capable of ...
|
|
WO/2023/153847A1 |
The present invention relates to a peptide ligand that specifically binds to carbonic anhydrase IX (CAIX), a peptide construct comprising same, and uses thereof. The CAIX-binding peptide ligand of the present invention contains D-amino a...
|
|
WO/2023/154898A1 |
Provided herein are methods for decreasing the toxicity of advanced ablative cancer therapies on neighboring organs. The methods herein provide spacing between single or multiple tumor cites and immediate healthy organs while maintaining...
|
|
WO/2023/150820A1 |
Processes for the synthesis of zirconium-89 radiolabelled biological polymer-chelate agent conjugates are provided. Radiolabelling is performed in the presence of a polycarboxylate buffer resulting in improved reaction kinetics and short...
|
|
WO/2023/150695A1 |
Provided are compounds, compositions, methods, and kits for increasing target specificity of a mannosylated carbohydrate polymeric therapeutic or diagnostic compound to reduce or eliminate localization of the mannosylated carbohydrate po...
|
|
WO/2023/150483A1 |
Disclosed are methods for using regional tau PET scans for identifying a subject having or suspected of having, diagnosing, and treating Alzheimer's disease. The methods are particularly useful for treating and diagnosing a patient as su...
|
|
WO/2023/148116A1 |
The present disclosure relates to new folate-conjugates comprising a 5-methyltetrahydro-folate, a radiometal chelator optionally coordinating a radiometal M, and the albumin binder 5-(p-iodophenyl)pentanoate, and further provides uses of...
|
|
WO/2023/148680A1 |
The present disclosure relates to methods of large scale synthesis of radionuclide complex solutions having a high activity for diagnostic and/or therapeutic purposes, their use in the commercial production of radioactive drug substances...
|
|
WO/2023/148115A1 |
The present disclosure relates to new folate-conjugates comprising a 5-methyltetrahydro-folate, a radiometal chelator optionally coordinating a radiometal M, and an albumin binder linked through a hydrophobic linker, and further provides...
|
|
WO/2023/150540A1 |
The invention provides metal chelating agents and metal complexes of these agents of use in therapeutic and diagnostic applications.
|
|
WO/2023/141722A1 |
Methods for treating or ameliorating cancer comprising administering to a mammal a NTSR-1 targeted radiopharmaceutical comprising a radionuclide chelated to a compound of formula I, and one or more checkpoint inhibitors.
|
|
WO/2023/143612A1 |
Disclosed are a peptide urea derivative, a pharmaceutical composition containing the peptide urea derivative, and an application of the peptide urea derivative. The derivative is as represented by formula I, wherein R is a group containi...
|
|
WO/2023/144723A1 |
Provided herein are immunoconjugates, such as radioimmunoconjugates, comprising a therapeutic moiety conjugated to an antibody or antigen binding domain with binding specificity for hK2. In certain embodiments, the hK2-specific immunocon...
|
|
WO/2023/146931A2 |
Radiolabeled liposomes can be used in the treatment of cancer. These local therapies can be used to treat cancers including, but not limited to, leptomeningeal metastases. In an embodiment, radiolabeled liposomes comprising (186Re) obisb...
|
|
WO/2023/145967A1 |
[Problem] To provide a novel compound that is promising as a probe for nuclear medical testing. [Solution] Provided is a compound represented by general formula (I) or a salt thereof.
|
|
WO/2023/146587A1 |
A radioactive thermogel suspension, including a thermogel and a plurality of radioactive yttrium phosphate particles suspended in the thermogel. The thermogel is PLGA-g-PEG. The thermogel contains less than 65 ppm stannous octanoate. The...
|
|
WO/2023/146975A1 |
Disclosed are compounds of Formula (I), pharmaceutically acceptable salts thereof, and methods of preparation thereof, wherein R1, Xa, Xb, Xc, and Xd are as described in the specification. Further disclosed is an isotopic mixture of a co...
|
|
WO/2023/143445A1 |
The present invention relates to the field of molecular virology and immunology, in particular to the field of hepatitis B virus (HBV) infection treatment. In particular, the present invention relates to an epitope peptide (or a variant ...
|
|
WO/2023/141719A1 |
Combination therapies comprising administering PSMA-targeted radiopharmaceuticals and one or more checkpoint inhibitors
|
|
WO/2023/141717A1 |
Methods for treating or ameliorating cancer comprising administering to a mammal a NTSR-1 targeted radiopharmaceutical comprising a radionuclide chelated to a compound of formula I, and DNA damage response inhibitors.
|
|
WO/2023/139203A1 |
The present invention relates to complexes comprising a PSMA targeting compound linked to a radionuclide such as 47Sc, 111In, 161Tb. These compounds, and pharmaceutical compositions comprising them, can be used for medical applications, ...
|
|
WO/2023/139150A1 |
The present invention relates to a composition comprising a solid carrier, a protein or a fragment thereof immobilized on the surface of the solid carrier, a protective layer to protect the protein or the fragment thereof by embedding th...
|
|
WO/2023/141518A2 |
The present invention refers to endohedral metallofullerene derivatives for use in the treatment of cancer and other proliferative diseases. In particular, the invention discloses the use of endohedral fullerene antibody conjugates and i...
|
|
WO/2023/137335A2 |
Provided are methods for treating a CD33-positive hematological malignancy, such as acute myelogenous leukemia or multiple myeloma, in a subject by administering to the subject hematopoietic stem cells (HSCs) or hematopoietic stem and pr...
|
|
WO/2023/135398A1 |
The present invention relates to a conjugate of formula (I) for medicinal use: (I), wherein Ac, the hooking head, the linking arm, the spacer, M and u are as defined in the description.
|
|
WO/2023/133645A1 |
Radiolabeled compounds that target fibroblast activation protein (FAP). The compounds have 1-6 radiolabeling groups and 1-6 FAP-targeting groups, connected by 1-11 linkers. FAP-targeting groups have the structure of Formula (I). R1a and ...
|
|
WO/2023/136712A1 |
The present invention relates to a dual-mode probe for detecting hydrogen sulfide and a use thereof and, more specifically, to a dual-mode probe that has excellent blood-brain barrier permeability and is capable of fluorescence and nucle...
|
|
WO/2023/135538A1 |
Systems, methods, and kits useful for detecting and locating internal bleeding, such as gastrointestinal bleeding, during active or inactive bleeding. In some embodiments, the systems, methods, and kits make use of a single photon emissi...
|
|
WO/2023/130587A1 |
The present invention relates to a water-soluble methylbenzene ether derivative, a positron nuclide probe and a nuclide marker, and preparation methods therefor and the uses thereof. Water-soluble side chains are introduced by means of d...
|
